Capricor Therapeutics (CAPR) closed the last trading session at $18.09, gaining 330.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $34.40 indicates a 90.2% upside potential. The average comprises five short-term price targets ranging from a low of $25 to a high of $43, with a standard deviation of $8.71. While the lowest estimate indicates an increase of 38.2% from the current ...